Oridonin: Potential in Combating Cancer and Overcoming Drug Resistance

Authors

  • Urvashi Jaiswal
  • Shaily Chaudhary
  • Dolly Mallick
  • Hariom Choudhary
  • Govind Dangi
  • Hariom Nagar
  • Hariom Yadav
  • Golu Solanki
  • Akash Yadav

Keywords:

Diterpenoid compound, Diterpenoid compound, carcinoma, carcinoma, cytotoxic effects, cytotoxic effects, chemo resistance, chemo resistance, multi-drug resistance, multi-drug resistance

Abstract

Cancer remains a leading cause of morbidity and mortality worldwide. Oridonin, a tetracyclic diterpenoid from Rabdosia rubescens, has gained significant research interest due to its neuroprotective, anti-inflammatory, and anticancer properties. Structural modifications have led to derivatives with enhanced pharmacological activity. While drug resistance remains a major challenge in chemotherapy, oridonin has demonstrated the ability to overcome resistance through multiple mechanisms, making it a promising candidate for cancer treatment.

Downloads

Download data is not yet available.

References

Q. B. Han, W. L. Xiao, Y. H. Shen, and H. D. Sun, “Ent-Kaurane Diterpenoids from Isodon rubescens var. rubescens,” Chemical and Pharmaceutical Bulletin, vol. 52, no. 6, pp. 767–769, 2004.

W. Xu, J. Sun, T.-T. Zhang et al., “Pharmacokinetic behaviors and oral bioavailability of oridonin in rat plasma,” Acta Pharmacologica Sinica, vol. 27, no. 12, pp. 1642–1646, 2006.

Fujita E, Nagao Y, Node M, Kaneko K, Nakazawa S, Kuroda H. Antitumor activity of the isodon diterpenoids: structural requirements for the activity. Cell Mol Life Sci 1976;32:203–6.

C. Li, E. Wang, Y. Cheng, and J. Bao, “Oridonin: an active diterpenoid targeting cell cycle arrest, apoptotic and autophagic pathways for cancer therapeutics, International Journal of Biochemistry & Cell Biology, vol. 43, no. 5, pp. 701–704, 2011.

Yang, H., Huang, J., Gao, Y., Wen, Z., Peng, L., and Ci, X. (2020). Oridonin Attenuates Carrageenan-Induced Pleurisy via Activation of the KEAP-1/Nrf2Pathway and Inhibition of the TXNIP/NLRP3 and NF-κB Pathway in Mice. Inflammopharmacol 28, 513–523. doi:10.1007/s10787-019-00644-y

He, S.-D., Huang, S.-G., Zhu, H.-J., Luo, X.-G., Liao, K.-H., Zhang, J.-Y., et al. (2020). Oridonin Suppresses Autophagy and Survival in Rheumatoid Arthritis Fibroblast-like Synoviocytes. Pharm. Biol. 58, 146–151. doi:10.1080/ 13880209.2020.1711783.

Liu, D.-L., Bu, H.-Q., Wang, W.-L., Luo, H., and Cheng, B.-N. (2020). Oridonin Enhances the Anti-tumor Activity of Gemcitabine towards Pancreatic Cancer by Stimulating Bax- and Smac-dependent Apoptosis. Transl Cancer Res. TCR 9, 4148–4161. doi:10.21037/tcr-19-3000

Shi, M., Deng, Y., Yu, H., Xu, L., Shi, C., Chen, J., et al. (2019). Protective Effects of Oridonin on Acute Liver Injury via Impeding Posttranslational Modifications of Interleukin-1 Receptor-Associated Kinase 4 (Irak4) in the Toll-like Receptor 4 (Tlr4) Signaling Pathway. Mediators Inflamm. 2019, 1–11. doi:10.1155/2019/ 7634761

Li, J., Bao, L., Zha, D., Zhang, L., Gao, P., Zhang, J., et al. (2018). Oridonin Protects against the Inflammatory Response in Diabetic Nephropathy by Inhibiting the TLR4/p38-MAPK and TLR4/NF-κB Signaling Pathways. Int. Immunopharmacology 55, 9–19. doi:10.1016/j.intimp.2017.11.040

Lu, C., Chen, C., Chen, A., Wu, Y., Wen, J., Huang, F., et al. (2020). Oridonin Attenuates Myocardial Ischemia/reperfusion Injury via Downregulating Oxidative Stress and Nlrp3 Inflammasome Pathway in Mice. Evidence-Based Complement. Altern. Med. 2020, 1–9. doi:10.1155/2020/7395187.

Zhang J., J., Zhou, Y., Sun, Y., Yan, H., Han, W., Wang, X., et al. (2019). Beneficial Effects of Oridonin on Myocardial Ischemia/reperfusion Injury: Insight Gained by Metabolomic Approaches. Eur. J. Pharmacol. 861, 172587. doi:10.1016/ j.ejphar.2019.172587

Xu, M., Wan, C.-x., Huang, S.-h., Wang, H.-b., Fan, D., Wu, H.-M., et al. (2019). Oridonin Protects against Cardiac Hypertrophy by Promoting P21-Related Autophagy. Cell Death Dis 10, 403. doi:10.1038/s41419-019-1617-y

Huang, W., Huang, M., Ouyang, H., Peng, J., and Liang, J. (2018). Oridonin Inhibits Vascular Inflammation by Blocking NF-κB and MAPK Activation. Eur. J. Pharmacol. 826, 133–139. doi:10.1016/j.ejphar.2018.02.044

Yang, H., Lv, H., Li, H., Ci, X., and Peng, L. (2019b). Oridonin Protects LPSInduced Acute Lung Injury by Modulating Nrf2-Mediated Oxidative Stress and Nrf2-independent NLRP3 and NF-κB Pathways. Cell Commun Signal 17, 62. doi:10.1186/s12964-019-0366-y

Fu, Y., Zhao, P., Xie, Z., Wang, L., and Chen, S. (2018). Oridonin Inhibits Myofibroblast Differentiation and Bleomycin-Induced Pulmonary Fibrosis by Regulating Transforming Growth Factor β (TGFβ)/Smad Pathway. Med. Sci. Monit. 24, 7548–7555. doi:10.12659/Msm.912740

Liu, H., Gu, C., Liu, M., Liu, G., and Wang, Y. (2020). Nek7 Mediated Assembly and Activation of Nlrp3 Inflammasome Downstream of Potassium Efflux in Ventilator-Induced Lung Injury. Biochem. Pharmacol. 177, 113998. doi:10.1016/j.bcp.2020.113998

B.A. Owona, H.J. Schluesener, Molecular insight in the multifunctional effects of oridonin, Drugs R D 15 (2015) 233–244.

S. Wang, Z. Zhong, J. Wan, W. Tan, G. Wu, M. Chen, Y. Wang, Oridonin induces apoptosis, inhibits migration and invasion on highly-metastatic human breast cancer cells, Am. J. Chin. Med. 41 (2013) 177–196.

G.B. Zhou, S.J. Chen, Z.Y. Wang, Z. Chen, Back to the future of oridonin: again, compound from medicinal herb shows potent antileukemia efficacies in vitro and in vivo, Cell Res. 17 (2007) 274–276.

R. Xia, S.X. Chen, Q. Qin, Y. Chen, W.W. Zhang, R.R. Zhu, A.M. Deng, Oridonin Suppresses proliferation of human ovarian cancer cells via blockage of mTOR Signaling, Asian Pac. J. Cancer Prev. 17 (2016) 667–671.

J. Yang, H. Jiang, C. Wang, B. Yang, L. Zhao, D. Hu, G. Qiu, X. Dong, B. Xiao, Oridonin triggers apoptosis in colorectal carcinoma cells and suppression of microRNA-32 expression augments oridonin-mediated apoptotic effects, Biomed. Pharmacother. 72 (2015) 125–134.

Q.Q. Liu, K. Chen, Q. Ye, X.H. Jiang, Y.W. Sun, Oridonin inhibits pancreatic cancer cell migration and epithelial-mesenchymal transition by suppressing Wnt/beta-catenin signaling pathway, Cancer Cell Int. 16 (2016) 57.

S. Gao, H. Tan, N. Zhu, H. Gao, C. Lv, J. Gang, Y. Ji, Oridonin induces apoptosis through the mitochondrial pathway in human gastric cancer SGC-7901 cells, Int. J. Oncol. 48 (2016) 2453–2460.

W.S. Zhou, Y.X. Cheng, The stereo-, regio-, and chemo-selective conversion of diterpenoids, kamebakaurin to oriaonin, Sci. China B 35 (1992) 194–199.

Xu, L., Bi, Y., Xu, Y., Zhang, Z., Xu, W., Zhang, S., et al. (2020). Oridonin Inhibits the Migration and Epithelial-to-mesenchymal Transition of Small Cell Lung Cancer Cells by Suppressing FAK-ERK1/2 Signalling Pathway. J. Cel Mol Med 24, 4480–4493. doi:10.1111/jcmm.15106

Yang J, Ren X, Zhang L, Li Y, Cheng B, Xia J. Oridonin inhibits oral cancer growth and PI3K/Akt signaling pathway. Biomedicine & Pharmacotherapy. 2018 Apr 1;100:226-32.

G.-B. Zhou, H. Kang, L. Wang et al., “Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo,” Blood, vol. 109, no. 8, pp. 3441–3450, 2007.

L. Zang, Q. Xu, Y. Ye et al., “Autophagy enhanced phagocytosis of apoptotic cells by oridonin-treated human histocytic lymphoma U937 cells,” Archives of Biochemistry and Biophysics, vol. 518, no. 1, pp. 31–41, 2012.

Ren KK, Wang HZ, Xie LP, Chen DW, Liu X, Sun J, Nie YC, Zhang RQ. The effects of oridonin on cell growth, cell cycle, cell migration and differentiation in melanoma cells. Journal of ethnopharmacology. 2006 Jan 16;103(2):176-80.

Tian L, Xie K, Sheng D, Wan X, Zhu G. Antiangiogenic effects of oridonin. BMC complementary and alternative medicine. 2017 Dec;17:1-5.

Liu DL, Bu HQ, Jin HM, Zhao JF, Li Y, Huang H. Enhancement of the effects of gemcitabine against pancreatic cancer by oridonin via the mitochondrial caspase-dependent signaling pathway. Molecular Medicine Reports. 2014 Dec 1;10(6):3027-34.

Cao S, Xia M, Mao Y, Zhang Q, Donkor PO, Qiu F, Kang N. Combined oridonin with cetuximab treatment shows synergistic anticancer effects on laryngeal squamous cell carcinoma: involvement of inhibition of EGFR and activation of reactive oxygen species-mediated JNK pathway. International Journal of Oncology. 2016 Nov 1;49(5):2075-87.

Wang Z, Li Y, Ahmad A, et al. Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance. Drug Resist Updates. 2010;13(4e5):109e118. https://doi.org/10.1016/j.drup. 2010.07.001.

Efferth T, Davey M, Olbrich A, Rücker G, Gebhart E, Davey R. Activity of drugs from traditional Chinese medicine toward sensitive and MDR1-or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells. Blood Cells, Molecules, and Diseases. 2002 Mar 1;28(2):160-8.

He Z, Xiao X, Li S, et al. Oridonin induces apoptosis and reverses drug resistance in cisplatin resistant human gastric cancer cells. Oncol Lett. 2017;14(2):2499e2504. https: //doi.org/10.3892/ol.2017.6421.

Yuan R, Hou Y, Sun W, et al. Natural products to prevent drug resistance in cancer chemotherapy: a review. Ann N Y Acad Sci. 2017;1401(1):19e27. https://doi.org/10.1111/nyas. 13387.

Weng H, Huang H, Dong B, Zhao P, Zhou H, Qu L. Inhibition of miR-17 and miR-20a by oridonin triggers apoptosis and reverses chemoresistance by derepressing BIM-S. Canc Res. 2014;74(16):4409e4419. https://doi.org/10.1158/0008-5472. Can-13-1748.

Kadioglu O, Saeed M, Kuete V, Greten HJ, Efferth T. Oridonin targets multiple drug-resistant tumor cells as determined by in silico and in vitro analyses. Front Pharmacol. 2018;9:355. https://doi.org/10.3389/fphar.2018.00355.

Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Canc Cell. 2002;2(2):117e125.

Kadioglu O, Saeed M, Kuete V, Greten HJ, Efferth T. Oridonin targets multiple drug-resistant tumor cells as determined by in silico and in vitro analyses. Frontiers in pharmacology. 2018 Apr 16;9:355.

Downloads

Published

2025-07-07

How to Cite

1.
Jaiswal U, Chaudhary S, Mallick D, Choudhary H, Dangi G, Nagar H, et al. Oridonin: Potential in Combating Cancer and Overcoming Drug Resistance. J Neonatal Surg [Internet]. 2025 Jul. 7 [cited 2026 Apr. 30];14(31S):921-5. Available from: https://jneonatalsurg.com/index.php/jns/article/view/8054

Issue

Vol. 14 No. 31S (2025): Journal of Neonatal Surgery

Section

Original Article

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

  • Adapt — remix, transform, and build upon the material for any purpose, even commercially.

Terms:

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.